Fat Burner approaches fat metabolism from three simultaneous angles; AOD-9604 triggers the breakdown of existing fat cells and prevents new ones from forming, CB4211 enhances the body's insulin sensitivity to improve how it metabolizes fat, and Tesamorelin targets visceral adipose tissue through growth hormone stimulation. Each compound contributes a specific and non-redundant mechanism, making the formulation more comprehensive than any single fat-targeting compound could achieve alone.
AOD-9604 is a synthetic fragment of the human growth hormone molecule, specifically the region responsible for HGH's fat-metabolizing properties. It stimulates lipolysis—the breakdown of stored fat cells into free fatty acids the body can use as fuel—and simultaneously inhibits lipogenesis, the process by which the body forms new fat cells. Critically, AOD-9604 produces these effects without influencing blood sugar levels or insulin response, addressing a key limitation of full human growth hormone therapy and making it suitable for a wider range of patients.
CB4211 is an analog of MOTS-C, a mitochondrial-derived peptide, engineered with enhanced properties compared to the natural compound. Its mechanism centers on insulin sensitivity: CB4211 potentiates the body's insulin response by extending insulin receptor activation, which improves fatty acid metabolism and supports glucose homeostasis. In practical terms, it helps the body process fatty acids more efficiently and reduces the release of free fatty acids from fat cells; within Fat Burner Blend, CB4211 supports the metabolic conditions under which the fat mobilized by AOD-9604 can be processed effectively.
Tesamorelin is a stabilized GHRH analog that stimulates growth hormone release with a demonstrated specificity for visceral adipose tissue. Visceral fat accumulates deep in the abdominal cavity, is metabolically disruptive, and resists conventional diet and exercise interventions; Tesamorelin addresses it directly through GH-mediated fat metabolism, complementing the lipolytic and metabolic mechanisms of the other compounds in the protocol.
Fat Burner is administered as a subcutaneous injection five mornings per week on an empty stomach. Fasted-state administration maximizes the fat-oxidizing conditions under which lipolytic compounds perform most effectively. Your RegenMD provider establishes your dosing protocol based on your metabolic profile and goals, and monitors your response across the five or ten-week program.
What This Means For You
- Stimulates lipolysis and fat cell breakdown
- Inhibits formation of new fat cells
- Targets visceral abdominal fat specifically
- Enhances insulin sensitivity and fatty acid metabolism
- Supports healthy glucose homeostasis
- Supports lipid metabolism and cardiovascular health
- Promotes a balanced inflammatory response
- Supports bone density and cartilage health
